Claims
- 1. At least one isolated mammalian RELP fusion antibody, comprising at least one heavy chain variable region comprising SEQ ID NO:7 and at least one light chain variable region comprising SEQ ID NO:8.
- 2. A composition, comprising at least one isolated mammalian RELP fusion antibody according to claim 1, and at least one biologically acceptable carrier or diluent.
- 3. An isolated nucleic acid encoding at least one isolated mammalian RELP fusion antibody according to claim 1.
- 4. An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 3.
- 5. A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 4.
- 6. A method for producing at least one RELP fusion antibody, comprising translating a nucleic acid according to claim 3 under conditions in vitro, in vivo or in situ, such that said RELP fusion antibody is expressed in detectable or recoverable amounts.
- 7. At least one RELP fusion antibody provided by a method according to claim 6.
- 8. At least one isolated mammalian RELP fusion antibody, comprising at least one heavy chain variable region comprising SEQ ID NO:27 and at least one light chain variable region comprising SEQ ID NO:28.
- 9. A composition, comprising at least one isolated mammalian RELP fusion antibody according to claim 8, and at least one biologically acceptable carrier or diluent.
- 10. An isolated nucleic acid encoding at least one isolated mammalian RELP fusion antibody according to claim 8.
- 11. An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 10.
- 12. A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 10.
- 13. A method for producing at least one RELP fusion antibody, comprising translating a nucleic acid according to claim 10 under conditions in vitro, in vivo or in situ, such that said RELP fusion antibody is expressed in detectable or recoverable amounts.
- 14. At least one RELP fusion antibody provided by a method according to claim 13.
- 15. At least one isolated mammalian RELP fusion antibody, comprising at least one light chain variable region comprising SEQ ID NO:39.
- 16. A composition, comprising at least one isolated mammalian RELP fusion antibody according to claim 15, and at least one biologically acceptable carrier or diluent.
- 17. An isolated nucleic acid encoding at least one isolated mammalian RELP fusion antibody according to claim 16.
- 18. An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 117.
- 19. A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 17.
- 20. A method for producing at least one RELP fusion antibody, comprising translating a nucleic acid according to claim 17 under conditions in vitro, in vivo or in situ, such that said RELP fusion antibody is expressed in detectable or recoverable amounts.
- 21. At least one RELP fusion antibody provided by a method according to claim 20.
PRIOR APPLICATION
[0001] This application is claims priority to U.S. application No. 60/385,305, filed Jun. 3, 1992, which is entirely incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60385305 |
Jun 2002 |
US |